Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions,
rewards, and special promotions.
Unfortunately, the antibody (ID:191057) is no longer available.
Below is a list of antibodies to the same protein target. You may also try your search again using the search box at the top of the page.
Please contact us if you have any questions.
Cdc14 / CDC14A
cell division cycle 14A
CDC14A, a homolog of the essential Saccharomyces cerevisiae cdc14 gene, is a member of the CDC14 subfamily. The gene product has been shown to dephosphorylate human Cdh1 and activate APC(Cdh1), the anaphase-promoting complex that ubiquitinates mitotic cyclins and allows cells to exit from mitosis. CDC14A also has been shown to interact with interphase centrosomes and to regulate the centrosome duplication cycle. At least three mRNA variants of CDC14A have been identified. Dispruption of centrosome duplication by overexpression or downregulation of CDC14 has been shown to cause aberrant chromosome partitioning into daughter cells leading to genomic instability in mammalian cells. The CDC14A protein has been reported to interact with the tumor suppressor protein p53 both in vitro and in vivo and may regulate the function of p53. CDC14A has been mapped to chromosome band 1p21, a region that has been shown to exhibit loss of heterozygosity in highly differentiated breast carcinoma and malignant mesothelioma. Further, a 48-bp in-frame deletion in the cDNA of the breast carcinoma cell line has been identified, and loss of expression of the wild type allele in this cell line supports the possibility that CDC14A may be a tumor suppressor gene that is targeted for inactivation during tumorigenesis.